12:00 AM
Apr 08, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

ChronVac-C: Interim Phase II data

Interim data from an open-label, Swedish Phase II trial in 29 treatment-naive patients with chronic HCV genotype 1 infection showed that 2 doses of 500 µg intramuscular ChronVac-C administered 4 weeks apart followed by Pegasys peginterferon alfa-2a and Copegus ribavirin did not significantly improve treatment outcomes at week 12 vs. Pegasys and Copegus alone. Specifically, ChronVac-C...

Read the full 277 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >